NasdaqGM - Nasdaq Real Time Price USD

Amicus Therapeutics, Inc. (FOLD)

Compare
11.25 -0.26 (-2.26%)
At close: September 10 at 4:00 PM EDT
Loading Chart for FOLD
DELL
  • Previous Close 11.51
  • Open 11.50
  • Bid 11.21 x 200
  • Ask 11.30 x 100
  • Day's Range 11.25 - 11.51
  • 52 Week Range 9.02 - 14.57
  • Volume 1,052,493
  • Avg. Volume 2,629,601
  • Market Cap (intraday) 3.337B
  • Beta (5Y Monthly) 0.69
  • PE Ratio (TTM) --
  • EPS (TTM) -0.39
  • Earnings Date Nov 6, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 17.36

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

amicusrx.com

500

Full Time Employees

December 31

Fiscal Year Ends

Recent News: FOLD

View More

Performance Overview: FOLD

Trailing total returns as of 9/10/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

FOLD
20.72%
S&P 500
15.21%

1-Year Return

FOLD
10.50%
S&P 500
23.29%

3-Year Return

FOLD
2.00%
S&P 500
22.31%

5-Year Return

FOLD
18.42%
S&P 500
84.51%

Compare To: FOLD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: FOLD

View More

Valuation Measures

Annual
As of 9/10/2024
  • Market Cap

    3.34B

  • Enterprise Value

    3.52B

  • Trailing P/E

    --

  • Forward P/E

    50.25

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.43

  • Price/Book (mrq)

    25.18

  • Enterprise Value/Revenue

    7.73

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -26.23%

  • Return on Assets (ttm)

    -2.15%

  • Return on Equity (ttm)

    -97.94%

  • Revenue (ttm)

    455.66M

  • Net Income Avi to Common (ttm)

    -119.54M

  • Diluted EPS (ttm)

    -0.39

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    260.06M

  • Total Debt/Equity (mrq)

    335.08%

  • Levered Free Cash Flow (ttm)

    12.99M

Research Analysis: FOLD

View More

Company Insights: FOLD

Research Reports: FOLD

View More

People Also Watch